Palmer Ashleigh's Form 4 filing
Provention Bio, Inc. (PRVB) · filed Feb 14, 2023
- Accession no.
- 0001493152-23-005076
- Filed
- Feb 14, 2023
- Trade date
- Feb 10-13, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $764.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Palmer AshleighCIK 0001493714 | Director, Officer (Director and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2023 | Common Stock | MOption exerciseAcquired | +50,000 | $2.50 | +$125,000 | 2,620,050 | Direct | |
| Feb 10, 2023 | Common Stock | SSaleDisposed | −50,000 | $10.11F2 | −$505,500 | 2,570,050 | Direct | |
| Feb 13, 2023 | Common Stock | MOption exerciseAcquired | +25,835 | $2.50 | +$64,587.5 | 2,595,885 | Direct | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −25,835 | $10.04F3 | −$259,383.4 | 2,570,050 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2023 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 467,555 | Direct | |
| Feb 13, 2023 | Common Stock | MOption exerciseDisposed | −25,835 | $0.00 | $0 | 441,720 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.28 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.42 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.